Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding Ltd
(OP:
RHHBF
)
284.70
-17.08 (-5.66%)
Streaming Delayed Price
Updated: 1:29 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
100
Open
284.70
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
301.78
Today's Range
284.70 - 284.70
52wk Range
243.42 - 368.43
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
April 09, 2024
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to reshape its workforce and tap local talent pools.
Via
Benzinga
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
January 02, 2024
Friday, LumiraDx Limited (NASDAQ: LMDX) appointed joint administrators for two subsidiaries.
Via
Benzinga
Exposures
COVID-19
Performance
YTD
-7.31%
-7.31%
1 Month
-0.35%
-0.35%
3 Month
-20.27%
-20.27%
6 Month
-10.47%
-10.47%
1 Year
-11.21%
-11.21%
More News
Read More
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
December 11, 2023
Via
Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
December 05, 2023
Via
Benzinga
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
December 04, 2023
Via
Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
Via
Benzinga
Exposures
Product Safety
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
October 23, 2023
Via
Benzinga
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products
October 19, 2023
Via
Benzinga
Exposures
COVID-19
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
Via
Benzinga
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready
October 11, 2023
Via
Benzinga
Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares
October 04, 2023
Via
Benzinga
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges
September 27, 2023
Via
Benzinga
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
September 21, 2023
Via
Benzinga
Exposures
COVID-19
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
Via
Benzinga
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer
September 01, 2023
Via
Benzinga
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time
August 30, 2023
Via
Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Via
Benzinga
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study
August 23, 2023
Via
Benzinga
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
August 21, 2023
Via
Benzinga
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
July 28, 2023
Via
Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
July 26, 2023
Via
Benzinga
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy
July 24, 2023
Via
Benzinga
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal
July 14, 2023
Via
Benzinga
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion
July 13, 2023
Via
Benzinga
Roche's Bispecific Antibody With Fixed-Duration Treatment Scores FDA Approval For Type Of Lymphoma
June 16, 2023
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.